What is rMark Bio?
Founded in 2015 by Jason M. Smith and Dr. Lev Becker, rMark Bio, Inc. operates at the intersection of life sciences and artificial intelligence. Headquartered in Chicago and Seattle, the company provides a holistic suite of services designed to simplify the adoption of AI within the pharmaceutical industry. By integrating strategy, technology, and human expertise, rMark Bio enables top-tier global pharmaceutical organizations to optimize their operational workflows and data utilization. The company maintains a strong ecosystem of industry-leading partners, including Microsoft, nVidia, and Google, which reinforces its market authority and technical credibility in a highly competitive sector.
How much funding has rMark Bio raised?
rMark Bio has raised a total of $1.6M across 2 funding rounds:
Angel/Seed
$1.5M
Debt
$150K
Angel/Seed (2019): $1.5M with participation from MATH Venture Partners, Lincoln Park Capital, SaaS Ventures, and M25 Group
Debt (2020): $150K led by PPP
Key Investors in rMark Bio
MATH Venture Partners
Math Venture Partners partners with founding teams to help them realize their vision and achieve growth with greater certainty, leveraging a track record of scaling businesses valued at over $7 billion.
M25 Group
M25 Group is a venture-focused firm that integrates logistics and digital trends to provide comprehensive support and sustainable solutions for growing businesses.
SaaS Ventures
SaaS Ventures is an investment firm specializing in early-stage software-as-a-service companies, providing the necessary capital and strategic guidance to foster rapid market adoption.
What's next for rMark Bio?
With the successful acquisition of $0, rMark Bio is well-positioned to accelerate its enterprise-level growth strategy. The firm is expected to prioritize the enhancement of its AI-driven analytics capabilities, aiming to deepen its penetration within the top 20 global pharmaceutical companies. Future strategic initiatives will likely focus on scaling its service delivery model and expanding its collaborative network with healthcare technology leaders. As the industry continues to demand more sophisticated, data-centric solutions, rMark Bio's focus on simplifying complex AI adoption will remain a key differentiator, driving long-term value for its stakeholders and clients alike.
See full rMark Bio company page
